Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

9,054 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Receptor-interacting protein kinase 2 (RIPK2) stabilizes c-Myc and is a therapeutic target in prostate cancer metastasis.
Yan Y, Zhou B, Qian C, Vasquez A, Kamra M, Chatterjee A, Lee YJ, Yuan X, Ellis L, Di Vizio D, Posadas EM, Kyprianou N, Knudsen BS, Shah K, Murali R, Gertych A, You S, Freeman MR, Yang W. Yan Y, et al. Among authors: lee yj. Nat Commun. 2022 Feb 3;13(1):669. doi: 10.1038/s41467-022-28340-6. Nat Commun. 2022. PMID: 35115556 Free PMC article.
27-hydroxycholesterol and DNA damage repair: implication in prostate cancer.
Galvan GC, Friedrich NA, Das S, Daniels JP, Pollan S, Dambal S, Suzuki R, Sanders SE, You S, Tanaka H, Lee YJ, Yuan W, de Bono JS, Vasilevskaya I, Knudsen KE, Freeman MR, Freedland SJ. Galvan GC, et al. Among authors: lee yj. Front Oncol. 2023 Dec 21;13:1251297. doi: 10.3389/fonc.2023.1251297. eCollection 2023. Front Oncol. 2023. PMID: 38188290 Free PMC article.
Iodine starch test in a peritoneal dialysis-related hydrothorax.
Lee YJ, Guo W, Wei Zhen Lee I, Shi Xian Kok S, Yeoh LY. Lee YJ, et al. Perit Dial Int. 2024 Nov 25:8968608241302700. doi: 10.1177/08968608241302700. Online ahead of print. Perit Dial Int. 2024. PMID: 39584802 No abstract available.
Efficacy and safety of mirikizumab in patients with moderately-to-severely active Crohn's disease: a phase 3, multicentre, randomised, double-blind, placebo-controlled and active-controlled, treat-through study.
Ferrante M, D'Haens G, Jairath V, Danese S, Chen M, Ghosh S, Hisamatsu T, Kierkus J, Siegmund B, Bragg SM, Crandall W, Durand F, Hon E, Lin Z, Lopes MU, Morris N, Protic M, Carlier H, Sands BE; VIVID Study Group. Ferrante M, et al. Lancet. 2024 Nov 21:S0140-6736(24)01762-8. doi: 10.1016/S0140-6736(24)01762-8. Online ahead of print. Lancet. 2024. PMID: 39581202
9,054 results